Independent medical education
The medical education activities below are non-promotional, evidenced-based, fair-balanced and can be accredited or non-accredited. The activities are developed independently by third-party providers through an educational grant from Johnson & Johnson to enhance the knowledge, skills, and performance of healthcare professionals, patients, and communities.
The links provided for the independent medical education activities direct you to the general website of the educational provider. Please note the title of the specific activity, as you will need to use the website’s search function to locate it. This approach is required to comply with accreditation guidelines.
What Clinicians Want to Know: Addressing Current Questions and Controversies in the Management of Multiple Myeloma
- AMCP: Addressing Barriers in Advancing Equitable Biomarker Testing in Community Oncology
- Bladder Cancer: Treatment Updates Part I of Living with Bladder Cancer (Patient Education) (12/24)
- Candid Conversations on Modern Urothelial Cancer Management: Personalizing Patient Care Using the Latest Evidence and Innovative Therapeutic Strategies
- For Caregivers: Practical Tips to Cope with Loved One’s Bladder Cancer Part II of Living with Bladder Cancer (Patient Education) (12/24)
- Harnessing Innovation in Bladder Cancer Care: Strategies for Effectively Implementing Modern Therapeutic Advances Across the Disease Continuum
- Oncology Today with Dr Neil Love: Special Edition — Management of Urothelial Bladder Cancer
- Opportunities for Improved Outcomes: The Role of Targeted Therapies in Metastatic Urothelial Carcinoma (12/24)
- NCCN Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care New Approaches to Treatment of Bladder Cancer (12/24)
- Vital Questions for Treatment of Bladder Cancer: Expert Insights on Recent and Near-Future Changes (12/24)
Non-small cell lung cancer
- AMCP: Addressing Barriers in Advancing Equitable Biomarker Testing in Community Oncology
- Biomarker Testing: Shaping Personalized Medicine (Episode 2)
- Can Molecular Testing Identify Which mNSCLC Patients Will Benefit From New Targeted Tx?
- Clinical Trials: How They Transform the Treatment of Cancer
- From Screening to Survivor Support: The Role of Primary Care Providers in the Management of Patients with EGFR-Mutant Non-Small Cell Lung Cancer (12/24)
- Highlights from Madrid on Perioperative Immunotherapy in Early-Stage NSCLC
- Highlights from Madrid on Targeted Therapy for Advanced NSCLC
- Interprofessional Approaches to Managing Adverse Events in EGFR-Mutated NSCLC
- Leading Developments and Current Questions in Lung Cancer Panel Discussions (Patient Education) (12/24)
- Navigating Rapid Sea Changes in First- and Later-Line Treatment of EGFR-Mutated NSCLC
- New Horizons in the Treatment and Management of Non-Small Cell Lung Cancer (NSCLC): Managed Care Considerations on the Role of EGFR Exon 20-Targeted Therapies
- Novel Therapeutics: Changing the Treatment Landscape for NSCLC (Episode 3)
- Practical Strategies for Preventing and Mitigating Toxicities of Targeted Therapy (Episode 4)
- Second Opinion: Investigators Discuss How They Apply Available Clinical Research in the Care of Patients with Non-Small Lung Cancer with EGFR Mutations
- The Evolution of Biomarker Testing: Revolutionizing Treatment of NSCLC (Episode 1)
- Updates and Evidence-Based Strategies in Non-Small Cell Lung Cancer: A Focus on Molecular Testing, Targeted Treatment, and Adverse Event Management (12/24)
- 2024 Great Debates & Updates in Lung Cancers: Targeted Strategies in the Management of Non-Small Cell Lung Cancer: A Focus on EFGR Gene Mutations
Prostate cancer
- Advancing The Latest Evidence in mCRPC Treatment Across VA Clinical Care Teams: A Regional Grand Rounds Series (12/24)
- AMCP: Addressing Barriers in Advancing Equitable Biomarker Testing in Community Oncology
- An Asembia Satellite Symposium: Innovations in Prostate Cancer: Unveiling Novel Therapies and the Role of the Specialty Pharmacist
- AUA2024 Prostate Cancer Courses and On-Demand Activities
- Consensus or Controversy? Clinical Investigators Provide Perspectives on the Current and Future Management of Prostate Cancer
- Elevating Optimal Care for Prostate Cancer: Applying Personalized Treatment Options to Improve Outcomes
- Evolving Paradigm of PARP Inhibitors and Combination Therapies for mCRPC
- Expert Context from AUA 2024: Revolutionizing Prostate Cancer Treatment
- “Hot Seat”: Experts Face Your Hot-Button Questions on Maximizing PARP Inhibitors in Patients with CRPC
- Improving the Overall Safety and Quality of Care for Your Patients with Metastatic Hormone-Sensitive Prostate Cancer: How Does Your Approach Compare with the Experts?
- Medscape Onsite: Prostate and Bladder Cancer Updates
- Navigating Therapeutic Choices in Prostate Cancer: Effective Decision-Making for Patient-Centric Care (12/24)
- Second Opinion: Investigators Discuss How They and Their Colleagues Apply Available Clinical Research in the Care of Patients with Prostate Cancer
- Treatment Advances for Advanced Prostate Cancer: Guideline Updates and Newer Therapies (12/24)
- The Evolving Landscape of Advanced Prostate Cancer Treatment: A Guidelines and Case-Based Discussion
- (2024 PUPC) Evidence-Based Strategies to Optimize Prostate Cancer Screening and Outcomes
